Could you imagine that a new treatment for curing leukaemia will never reach the children it could cure, just because the scientific team that discovered it, is keeping it on the bench or at preclinical level, as no pharmaceutical company is interested to commercialise it.
And the scientific team is not even able to create a start-up as they dont know how to do it.

That is an example describing the gap that sometimes exists between discovery and availability to patient.

But we believe that it can be changed if most scientists are aware of the bridges needed from discovery to market.

We, at EUROBIOBIZ, are dedicated to help and support scientists willing to transfer the technology they have invented to the potential end-users.

Since 1999 we have developed tools to help scientists to understand how to link science and business.
From our recognised expertise in training through our collaboration with the European Commission for the Biobiz workshops (more than 500 scientists trained), to our dedicated investment evaluation practice and coaching activities, we have been instrumental at the creation of more than 50 biotech companies in Europe, and we are planning to continue.

Our team is made of individuals who have acquired this double experience of Science and Business in different places, from big pharmaceutical companies to real spin off from Universities.

Our customers are among the most prestigious academic research institutions, governmental agencies, business incubators, companies and investors in Europe and USA but are also coming from developing countries.

We are committed to support the development of Biotechnology for the benefit of the citizens of the World by Linking Life Sciences to Business

Michel G Lepers
President EUROBIOBIZ SAS
Associated Professor of Universit Auvergne
Technologies Transfer Office